Compare ACFN & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACFN | ECOR |
|---|---|---|
| Founded | 1986 | 2005 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.8M | 49.1M |
| IPO Year | N/A | 2018 |
| Metric | ACFN | ECOR |
|---|---|---|
| Price | $18.39 | $6.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 12.5K | ★ 67.1K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $32,032,000.00 |
| Revenue This Year | N/A | $33.60 |
| Revenue Next Year | N/A | $30.40 |
| P/E Ratio | $6.63 | ★ N/A |
| Revenue Growth | N/A | ★ 27.20 |
| 52 Week Low | $12.42 | $4.16 |
| 52 Week High | $33.00 | $8.55 |
| Indicator | ACFN | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 49.43 | 48.38 |
| Support Level | $18.16 | $4.65 |
| Resistance Level | $19.87 | $7.80 |
| Average True Range (ATR) | 0.99 | 0.61 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 63.27 | 38.06 |
Acorn Energy Inc is a holding company that focuses on technology-driven solutions for energy infrastructure asset management. The company operates through two segments namely, the PG segment and the CP segment. PG segment provides wireless remote monitoring and control systems and services for critical assets as well as Internet of Things applications which account for the majority of the revenue. CP segment is engaged in providing remote monitoring of cathodic protection systems on gas pipelines for gas utilities and pipeline companies.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.